Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bonesupport Brings In Former DePuy Exec As Head of North American Sales

Executive Summary

Bonesupport has appointed a new general manager to oversee sales in North America as it steps up commercial efforts of its Cerament bone void filler platform.

You may also be interested in...

Bonesupport Banks In More Cash, Pharma Expertise For Bioceramic Bone

Bone substitute materials specialist Bonesupport has strengthened its cash position with an influx of new capital, as well as installed a new chairman to strengthen its pharma know-how as it seeks to grow its drug-eluting bone scaffold business.

Bonesupport taps pharma veteran for CEO

Bonesupport, a Swedish specialist in injectable bone substitutes and drug-eluting bone scaffolds, has appointed Richard Davies as CEO. Davies’ experience has mainly been with pharma companies, including Eli Lilly and Amgen, where he held various senior roles managing different geographic markets. Prior to joining Lund-based Bonesupport, he served as chief commercial offer at Hospira, before it was acquired by Pfizer last year. Davies replaces Lloyd Diamond, who will transition to the role of chief business officer. The latter will re-locate back to the US and help drive commercial growth of Bonesupport’s lead product, Cerament, in that market. In his four years as Bonesupport’s CEO, Diamond took the company past the R&D phase and into commercialization. The new CEO expects his pharmaceutical experience will help leverage the drug-eluting capabilities of Cerament.

Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts